Autotaxin inhibition with PF-8380 enhances the radiosensitivity of human and murine glioblastoma cell lines

Frontiers in Oncology

Volumn 3 SEP, Issue , 2013, Pages

  Bhave, Sandeep R ^a   Dadey, David Y A ^a   Karvas, Rowan M ^a   Ferraro, Daniel J ^a   Kotipatruni, Rama P ^a   Jaboin, Jerry J ^a   Hallahan, Andrew N ^a   DeWees, Todd A ^a   Linkous, Amanda G ^b   Hallahan, Dennis E ^a,c,d,e   Thotala, Dinesh ^a,c,d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Washington University in St Louis School of Medicine   (United States)

^e WASHINGTON UNIVERSITY   (United States)

Author keywords

Autotaxin; Glioblastoma; Lysophosphatidic acid; PF 8380; Radiosensitizer

Indexed keywords

ACTIN; ANTINEOPLASTIC AGENT; AUTOTAXIN; LYSOPHOSPHATIDIC ACID; MESSENGER RNA; PF8380; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL DEATH; CELL MIGRATION; CLONOGENIC ASSAY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RADIOSENSITIVITY; RADIOSENSITIZATION; REAL TIME POLYMERASE CHAIN REACTION; SKINFOLD; TUMOR GROWTH; TUMOR INVASION; TUMOR VOLUME; WESTERN BLOTTING; WOUND HEALING;

EID: 84891106027     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00236     Document Type: Article

References (51)

1. Stupp R, Hegi ME, Van Den Bent MJ, Mason WP, Weller M, Mirimanoff RO, et al. Changing paradigms-an update on the multidisciplinary management of malignant glioma. Oncologist (2006) 11:165-245. doi:10.1634/theoncologist.11-2-165
2. Hoelzinger D, Demuth T, Berens M. Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Natl Cancer Inst (2007) 99:1583-676. doi:10.1093/jnci/djm187
3. Holland E. Glioblastoma multiforme: the terminator. Proc Natl Acad Sci U S A (2000) 97:6242-6. doi:10.1073/pnas.97.12.6242
4. Stupp R, Hegi ME, Mason WP, Van Den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol (2009) 10:459-66. doi:10.1016/S1470-2045(09)70025-7
5. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature (1992) 359:845-8. doi:10.1038/359845a0
6. Hovinga KE, Stalpers LJ, van Bree C, Donker M, Verhoeff JJ, Rodermond HM, et al. Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastoma multiforme cell lines-a clue to radioresistance? J Neurooncol (2005) 74:99-103. doi:10.1007/s11060-004-4204-7
7. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res (1999) 59:3374-8.
8. Wachsberger PR, Burd R, Cardi C, Thakur M, Daskalakis C, Holash J, et al. VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys (2007) 67:1526-37. doi:10.1016/j.ijrobp.2006.11.011
9. Verhoeff JJ, Stalpers LJ, Claes A, Hovinga KE, Musters GD, Peter Vandertop W, et al. Tumour control by whole brain irradiation of anti-VEGF-treated mice bearing intracerebral glioma. Eur J Cancer (2009) 45:3074-80. doi:10.1016/j.ejca.2009.08.004
10. Kester HC, Uitzetter JH, de Graaff LH, Visser J. A rapid purification procedure for pyruvate kinase from the hyphal fungus Aspergillus nidulans. Can J Microbiol (1988) 34:1154-8. doi:10.1139/m88-203
11. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol (2009) 27:4733-40. doi:10.1200/JCO.2008.19.8721
12. Grabenbauer GG, Gerber KD, Ganslandt O, Richter A, Klautke G, Birkmann J, et al. Effects of concurrent topotecan and radiation on 6-month progression-free survival in the primary treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys (2009) 75:164-9. doi:10.1016/j.ijrobp.2009.04.015
13. Biddlestone-Thorpe L, Sajjad M, Rosenberg E, Beckta JM, Valerie NC, Tokarz M, et al. ATM kinase inhibition preferentially sensitizes p53-mutant glioma to ionizing radiation. Clin Cancer Res (2013) 19:3189-200. doi:10.1158/1078-0432.CCR-12-3408
14. Hess C, Vuong V, Hegyi I, Riesterer O, Wood J, Fabbro D, et al. Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer (2001) 85:2010-6. doi:10.1054/bjoc.2001.2166
15. Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, et al. Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol (2011) 103:325-32. doi:10.1007/s11060-010-0390-7
16. Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, et al. The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res (2005) 65:7462-9. doi:10.1158/0008-5472.CAN-05-0071
17. Butowski N, Chang SM, Lamborn KR, Polley MY, Pieper R, Costello JF, et al. Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma. Neuro Oncol (2011) 13:1331-8. doi:10.1093/neuonc/nor130
18. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 455:1061-8. doi:10.1038/nature07385
19. Chakravarti A, Wang M, Robins HI, Lautenschlaeger T, Curran WJ, Brachman DG, et al. RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys (2013) 85:1206-11. doi:10.1016/j.ijrobp.2012.10.008
20. Uhm JH, Ballman KV, Wu W, Giannini C, Krauss JC, Buckner JC, et al. Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074. Int J Radiat Oncol Biol Phys (2011) 80:347-53. doi:10.1016/j.ijrobp.2010.01.070
21. Manning B, Cantley L. AKT/PKB signaling: navigating downstream. Cell (2007) 129:1261-335. doi:10.1016/j.cell.2007.06.009
22. McDowell K, Riggins G, Gallia G. Targeting the AKT pathway in glioblastoma. Curr Pharm Des (2011) 17:2411-31. doi:10.2174/138161211797249224
23. Zhang H, Xu X, Gajewiak J, Tsukahara R, Fujiwara Y, Liu J, et al. Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res (2009) 69:5441-9. doi:10.1158/0008-5472.CAN-09-0302
24. Nakamura JL, Karlsson A, Arvold ND, Gottschalk AR, Pieper RO, Stokoe D, et al. PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas. J Neurooncol (2005) 71:215-37. doi:10.1007/s11060-004-1718-y
25. Linkous A, Geng L, Lyshchik A, Hallahan D, Yazlovitskaya E. Cytosolic phospholipase A2: targeting cancer through the tumor vasculature. Clin Cancer Res (2009) 15:1635-79. doi:10.1158/1078-0432.CCR-08-1905
26. Yazlovitskaya E, Linkous A, Thotala D, Cuneo K, Hallahan D. Cytosolic phospholipase A2 regulates viability of irradiated vascular endothelium. Cell Death Differ (2008) 15:1641-94. doi:10.1038/cdd.2008.93
27. Linkous A, Yazlovitskaya E. Novel therapeutic approaches for targeting tumor angiogenesis. Anticancer Res (2012) 32:1-13.
28. Schleicher SM, Thotala DK, Linkous AG, Hu R, Leahy KM, Yazlovitskaya EM, et al. Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature. PLoS ONE (2011) 6(7):e22182. doi:10.1371/journal.pone.0022182
29. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, Takio K, et al. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol (2002) 158:227-60. doi:10.1083/jcb.200204026
30. Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, Yasuda K, et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem (2002) 277:39436-78. doi:10.1074/jbc.M205623200
31. van Meeteren L, Moolenaar W. Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res (2007) 46:145-205. doi:10.1016/j.plipres.2007.02.001
32. Nishimasu H, Okudaira S, Hama K, Mihara E, Dohmae N, Inoue A, et al. Crystal structure of autotaxin and insight into GPCR activation by lipid mediators. Nat Struct Mol Biol (2011) 18:205-12. doi:10.1038/nsmb.1998
33. Mills G, Moolenaar W. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer (2003) 3:582-673. doi:10.1038/nrc1143
34. Braddock D. Autotaxin and lipid signaling pathways as anticancer targets. Curr Opin Investig Drugs (2010) 11:629-66.
35. Yang Y, Mou L, Liu N, Tsao M. Autotaxin expression in non-small-cell lung cancer. Am J Respir Cell Mol Biol (1999) 21:216-38. doi:10.1165/ajrcmb.21.2.3667
36. Xu Y, Gaudette DC, Boynton JD, Frankel A, Fang XJ, Sharma A, et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res (1995) 1:1223-55.
37. Yang SY, Lee J, Park CG, Kim S, Hong S, Chung HC, et al. Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin Exp Metastasis (2002) 19:603-11.
38. Kishi Y, Okudaira S, Tanaka M, Hama K, Shida D, Kitayama J, et al. Autotaxin is overexpressed in glioblastoma multiforme and contributes to cell motility of glioblastoma by converting lysophosphatidylcholine to lysophosphatidic acid. J Biol Chem (2006) 281:17492-500. doi:10.1074/jbc.M601803200
39. Hoelzinger DB, Mariani L, Weis J, Woyke T, Berens TJ, McDonough WS, et al. Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia (2005) 7:7-23. doi:10.1593/neo.04535
40. Gierse J, Thorarensen A, Beltey K, Bradshaw-Pierce E, Cortes-Burgos L, Hall T, et al. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. J Pharmacol Exp Ther (2010) 334:310-7. doi:10.1124/jpet.110.165845
41. Hall EJ, Giaccia AJ. Radiobiology for the Radiologist. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins (2012).
42. Kotipatruni RP, Ferraro DJ, Ren X, Vanderwaal RP, Thotala DK, Hallahan DE, et al. NDRG4, the N-Myc downstream regulated gene, is important for cell survival, tumor invasion and angiogenesis in meningiomas. Integr Biol (Camb) (2012) 4:1185-97.
43. Leunig M, Yuan F, Menger MD, Boucher Y, Goetz AE, Messmer K, et al. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res (1992) 52:6553-60.
44. Stupp R, Mason WP, Van DenBent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 352:987-96. doi:10.1056/NEJMoa043330
45. Ptaszynska M, Pendrak M, Stracke M, Roberts D. Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration. Mol Cancer Res (2010) 8:309-30. doi:10.1158/1541-7786.MCR-09-0288
46. Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, et al. LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol (2010) 50:157-243. doi:10.1146/annurev.pharmtox.010909.105753
47. Ho JN, Lee SB, Lee SS, Yoon SH, Kang GY, Hwang SG, et al. Phospholipase A2 activity of peroxiredoxin 6 promotes invasion and metastasis of lung cancer cells. Mol Cancer Ther (2010) 9:825-32. doi:10.1158/1535-7163.MCT-09-0904
48. Heasley LE, Thaler S, Nicks M, Price B, Skorecki K, Nemenoff RA. Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer. J Biol Chem (1997) 272:14501-4. doi:10.1074/jbc.272.23.14501
49. Liu S, Umezu-Goto M, Murph M, Lu Y, Liu W, Zhang F, et al. Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. Cancer Cell (2009) 15:539-50. doi:10.1016/j.ccr.2009.03.027
50. Narayan RS, Fedrigo CA, Stalpers LJ, Baumert BG, Sminia P. Targeting the Akt-pathway to improve radiosensitivity in glioblastoma. Curr Pharm Des (2013) 19:951-7. doi:10.2174/138161213804547286
51. van Meeteren LA, Ruurs P, Stortelers C, Bouwman P, van Rooijen MA, Pradère JP, et al. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development. Mol Cell Biol (2006) 26:5015-37. doi:10.1128/MCB.02419-05